Stocks
Bristol-Myers Squibb CompanyBMY
NYSEHealthcarePharmaceuticals$59.08+0.22%
A global biopharmaceutical company focused on developing and commercializing prescription medicines for oncology, hematology, immunology, cardiovascular, and neuroscience diseases. Its portfolio includes blockbuster therapies such as Opdivo and Eliquis, which drive a significant share of revenue alongside a growing pipeline of biologics and specialty drugs. Investors track the company for patent expiration risks, pipeline development milestones, and capital allocation decisions that shape long-term earnings growth.
Market Cap: $120.3B52W Range: $42.52 – $62.89
Congressional Interest in Bristol-Myers Squibb Company (BMY)
13 members of Congress have disclosed 50 trades in Bristol-Myers Squibb Company (BMY), a Healthcare company. The buy/sell breakdown shows 22 purchases versus 28 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
13
Buys
22
Sells
28
Who in Congress Is Trading BMY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-27 | Alan Armstrong | buy | $1K – $15K |
| 2026-02-05 | Rohit Khanna | buy | $1K – $15K |